PL4114466T3 - Leczenie bólu i zwężenia naczyń - Google Patents

Leczenie bólu i zwężenia naczyń

Info

Publication number
PL4114466T3
PL4114466T3 PL21715057.2T PL21715057T PL4114466T3 PL 4114466 T3 PL4114466 T3 PL 4114466T3 PL 21715057 T PL21715057 T PL 21715057T PL 4114466 T3 PL4114466 T3 PL 4114466T3
Authority
PL
Poland
Prior art keywords
vasoconstriction
pain
treatment
Prior art date
Application number
PL21715057.2T
Other languages
English (en)
Inventor
Andrew Sternlicht
Original Assignee
Aisa Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aisa Pharma, Inc. filed Critical Aisa Pharma, Inc.
Publication of PL4114466T3 publication Critical patent/PL4114466T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL21715057.2T 2020-03-06 2021-03-05 Leczenie bólu i zwężenia naczyń PL4114466T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062986544P 2020-03-06 2020-03-06
US202063013468P 2020-04-21 2020-04-21
PCT/US2021/021218 WO2021178903A1 (en) 2020-03-06 2021-03-05 Treatment of pain and vasoconstriction

Publications (1)

Publication Number Publication Date
PL4114466T3 true PL4114466T3 (pl) 2025-04-28

Family

ID=75267628

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21715057.2T PL4114466T3 (pl) 2020-03-06 2021-03-05 Leczenie bólu i zwężenia naczyń

Country Status (8)

Country Link
US (2) US20230115611A1 (pl)
EP (2) EP4523748A3 (pl)
AU (1) AU2021231064A1 (pl)
CA (1) CA3174618A1 (pl)
ES (1) ES3014743T3 (pl)
MX (1) MX2022011041A (pl)
PL (1) PL4114466T3 (pl)
WO (1) WO2021178903A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3202575A1 (en) 2020-11-25 2022-06-02 Aisa Pharma, Inc. Treatment of raynaud's disease
US11736573B2 (en) * 2021-12-10 2023-08-22 Topia Interactive, Inc. Client authoritative state distribution system
WO2023150336A1 (en) * 2022-02-07 2023-08-10 Aisa Pharma, Inc. Methods of treating complex regional pain syndrome
WO2024102346A1 (en) * 2022-11-08 2024-05-16 Aisa Pharma, Inc. Methods of treating eye pain and eye disorders
WO2024196949A1 (en) 2023-03-20 2024-09-26 Aisa Pharma, Inc. Treatment of scleroderma
US20240358693A1 (en) 2023-04-06 2024-10-31 Aisa Pharma, Inc. Methods of treating pain
WO2025010067A1 (en) * 2023-07-06 2025-01-09 Smith Genetics Research Llc Treatment of autonomic dysfunction resulting from opioid use

Also Published As

Publication number Publication date
EP4114466C0 (en) 2024-12-04
AU2021231064A1 (en) 2022-09-22
EP4114466A1 (en) 2023-01-11
US20240366578A1 (en) 2024-11-07
CA3174618A1 (en) 2021-09-10
US20230115611A1 (en) 2023-04-13
EP4523748A2 (en) 2025-03-19
MX2022011041A (es) 2022-12-02
ES3014743T3 (en) 2025-04-24
EP4523748A3 (en) 2025-06-11
EP4114466B1 (en) 2024-12-04
WO2021178903A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
PL4114466T3 (pl) Leczenie bólu i zwężenia naczyń
EP4090658A4 (en) THERAPEUTIC AGENTS AND METHODS OF TREATMENT
CA3254619A1 (en) SINGLE-STRIP SPLINTS AND METHODS OF USE
GB202019475D0 (en) Therapeutic compounds and their use
GB202108572D0 (en) Therapeutic compounds and their use
IL304628A (en) Treatment of skin disorders
IL309317A (en) Treatment of diseases and disorders associated with MTRES1
IL307752A (en) Intracardiac device and methods of use
AU2024221819A1 (en) Treatment of opioid-induced pain
IL320242A (en) Compounds and their use for the treatment of hemoglobinopathy
IL315446A (en) Devices and methods for treating stretched skin
IL312428A (en) Use of Maribavir for treatment and their treatment methods
GB202116774D0 (en) Treatment of pain
IL311129A (en) Methods for the prevention and treatment of pain and related symptoms
GB202105665D0 (en) Inteligent disposable devices for wound therapy and treatment
GB202206359D0 (en) Treatment of pain
IL320820A (en) Therapeutic combinations of captopril and ventocalix
GB202011055D0 (en) Treatment of post-operative pain
GB202100761D0 (en) Treatment of osteoarthritic pain
HK40113814A (en) Methods of preventing and treating pain and associated symptoms
CA3276342A1 (en) DIAGNOSIS AND TREATMENT OF LONG COVID-19
HK40101934A (en) Treatment of pain and neurological conditions
GB202413915D0 (en) treatment of drug use
HK40112978A (zh) 疼痛的治疗
HK40082003A (en) Therapeutic agents and methods of treatment